Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORETHINDRONE vs DROSPIRENONE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Norethindrone is a synthetic progestin that binds to progesterone receptors, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and inducing secretory changes in the endometrium. It also has weak androgenic and estrogenic activity.
Spironolactone analog that antagonizes aldosterone at the mineralocorticoid receptor, leading to increased sodium and water excretion and potassium retention. Also has antiandrogenic activity by blocking androgen receptors and decreasing ovarian androgen production via inhibition of gonadotropin release.
Contraception,Abnormal uterine bleeding,Endometriosis,Amenorrhea,Dysmenorrhea,Off-label: Hormone therapy in transgender individuals
FDA-approved for oral contraception in combination with ethinyl estradiol,Treatment of moderate acne vulgaris in women ≥14 years,Treatment of premenstrual dysphoric disorder (PMDD) in women,Off-label: Hirsutism, polycystic ovary syndrome (PCOS), hypertension, edema
5 mg orally once daily for 5 days starting on day 5 of menstrual cycle or 0.35 mg orally once daily for contraception.
3 mg orally once daily.
Terminal elimination half-life: 5-14 hours (mean 8-10 hours); clinical context: requires once-daily dosing for steady state after ~2 days (5 half-lives).
Terminal elimination half-life: ~30-35 hours (range 25-40 h); significant clinical accumulation occurs after repeated dosing, requiring 10-14 days to reach steady state.
Primarily hepatic via reduction and conjugation. Major enzyme: CYP3A4. Also undergoes glucuronidation and sulfation.
No dose adjustment required for GFR >30 m L/min; use with caution if GFR <30 m L/min due to potential fluid retention.
Contraindicated in GFR <30 m L/min/1.73m2. No adjustment for mild-to-moderate impairment.
Contraindicated in severe hepatic impairment (Child-Pugh C); for mild to moderate (Child-Pugh A or B), use with caution and reduce dose if needed.
Cigarette smoking increases the risk of serious cardiovascular events (e.g., thromboembolism, stroke, myocardial infarction) with combined hormonal contraceptives. Risk increases with age (especially over 35) and with heavy smoking (≥15 cigarettes/day). Norethindrone-only pills have lower risk, but smoking still increases cardiovascular risk.
First trimester: Association with cardiovascular defects (e.g., VSD), limb reduction defects, and neural tube defects based on observational studies; risk is dose-dependent. Second/third trimesters: Potential for androgenic effects on female fetuses (pseudohermaphroditism), feminization of male fetuses, and increased risk of low birth weight. Not recommended for use during pregnancy due to known risks.
Category X. Contraindicated in pregnancy. First trimester: increased risk of congenital anomalies (e.g., cardiovascular, neural tube defects). Second/third trimesters: potential for fetal harm (e.g., masculinization of female fetus due to antiandrogenic activity).
Norethindrone is a progestin used for contraception, endometriosis, and abnormal uterine bleeding. It can cause androgenic side effects like acne and hirsutism. In high doses, it may impair glucose tolerance. Monitor liver function in patients with hepatic impairment. It is not effective as emergency contraception.
Monitor serum potassium levels in patients with renal impairment or those on potassium-sparing diuretics, ACE inhibitors, or ARBs due to antimineralocorticoid activity. Avoid use in patients with adrenal insufficiency. Drospirenone has a 3-day half-life; contraception efficacy is maintained if missed pills are taken within 12 hours.
No interactions on record
"Drospirenone may increase the hyperkalemic activities of Olopatadine."
"The serum concentration of Rilpivirine can be decreased when it is combined with Drospirenone."
"Drospirenone may increase the hyperkalemic activities of Pimecrolimus."
NORETHINDRONE and DROSPIRENONE are distinct pharmacological agents. NORETHINDRONE belongs to the Progestin class and is primarily used for ContraceptionAbnormal uterine bleedingEndometriosisAmenorrheaDysmenorrheaOff-label: Hormone therapy in transgender individuals. DROSPIRENONE belongs to the Progestin class and is primarily used for FDA-approved for oral contraception in combination with ethinyl estradiolTreatment of moderate acne vulgaris in women ≥14 yearsTreatment of premenstrual dysphoric disorder (PMDD) in womenOff-label: Hirsutism, polycystic ovary syndrome (PCOS), hypertension, edema. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. NORETHINDRONE carries a safety status of Category D/X, whereas DROSPIRENONE safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Extensively metabolized via CYP3A4 to inactive metabolites; minor contribution from CYP1A1 and CYP2C19. Undergoes hepatic glucuronidation.
Renal (30-50% as glucuronide conjugates, 5-10% unchanged), fecal (<10%)
Renal: ~50% (as metabolites; <10% unchanged); Fecal: ~40-50% (as metabolites; bile-mediated); Urinary and fecal elimination account for >95% of an oral dose.
~80% bound, primarily to sex hormone-binding globulin (SHBG) and albumin
97% bound to serum albumin; does not bind to sex hormone-binding globulin (SHBG) or corticosteroid-binding globulin (CBG).
4-7 L/kg (mean 5.5 L/kg); distribution into tissues, including breast milk, with lipophilic properties.
~4 L/kg (apparent Vd 4 L/kg), indicating extensive distribution into extravascular tissues, including breast milk.
Oral: 65-85% (extensive first-pass metabolism)
Oral: ~76% (absolute bioavailability) due to first-pass metabolism; food does not significantly affect absorption.
Contraindicated in Child-Pugh Class C. Not recommended in Class B.
Not indicated for use in pediatric patients for contraceptive purposes; for endometriosis, 2.5-5 mg orally twice daily starting at age 18.
Not established for use in pediatric patients.
No specific dose adjustment; use lowest effective dose due to increased risk of thromboembolic events and cognitive effects.
Use with caution; increased risk of hyperkalemia in elderly with impaired renal function.
Drospirenone-containing oral contraceptives may increase the risk of venous thromboembolism (VTE) compared to those containing levonorgestrel or other progestins. Smoking increases this risk, especially in women over 35.
Thromboembolic disorders, cardiovascular risk in smokers, liver disease, hypertension, diabetes, lipid effects, fluid retention, depression, migraine, irregular bleeding, ectopic pregnancy risk, reduced bone density with long-term use.
Breast cancer, undiagnosed vaginal bleeding, pregnancy, active liver disease, known or suspected pregnancy, history of thromboembolic disorders (e.g., DVT, PE), hypersensitivity to norethindrone.
No significant food interactions. Grapefruit juice may slightly increase norethindrone levels, but clinical effect is minimal.
Avoid excessive potassium-rich foods (e.g., bananas, oranges, spinach) if at risk for hyperkalemia. No specific food restrictions otherwise; grapefruit juice does not interact significantly.
Norethindrone is excreted into breast milk with an estimated milk-to-plasma ratio (M/P) of approximately 0.09 (range 0.01-0.2). Infant dose is less than 1% of maternal weight-adjusted dose. No adverse effects reported in infants but theoretical risk of hormonal effects. Consider alternative progestin-only contraceptives with established safety in lactation.
Excreted in breast milk in low amounts; M/P ratio not established. Caution advised. Use only if clearly needed, consider alternative contraception.
No established recommended dose adjustment; however, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce efficacy. Norethindrone is contraindicated in pregnancy; if exposure occurs, assess risks and consider alternative management. No specific dose increase is recommended.
No dose adjustment applicable as drug is contraindicated in pregnancy. Discontinue immediately if pregnancy occurs.
Take at the same time each day to maintain consistent hormone levels.,If you miss a dose, take it as soon as remembered, but if more than 12 hours late, skip it and use backup contraception.,Report heavy vaginal bleeding, severe pelvic pain, or signs of venous thromboembolism (chest pain, leg swelling) immediately.,This medication does not protect against sexually transmitted infections.,May cause breakthrough bleeding, especially in the first few months.
Take the pill at the same time every day to maintain effectiveness.,Do not use if you have kidney, liver, or adrenal gland problems.,Report symptoms of hyperkalemia such as muscle weakness or irregular heartbeat.,Use backup contraception if you miss a pill or experience vomiting/diarrhea.